Table 1 Characterization of the study group prior IM therapy
Characteristics |  | Patients n (%) or mean ± SD |
|---|---|---|
Median age, years [range] |  | 50.48 ± 12.51 [22–70] |
Gender | Male | 16 (64.0%) |
Female | 9 (36.0%) | |
Classify of preoperative therapy | IM therapy in locally advanced GISTs | 18 (72.0%) |
IM therapy in recurrent/metastasis GISTs | 7 (28.0%) | |
Primary localization | Stomach | 14 (56.0%) |
Duodenum | 4 (16.0%) | |
Jejuno-ileum | 1 (4.0%) | |
Rectum | 4 (16.0%) | |
Pelvic/retroperitoneal | 2 (8.0%) | |
Dose of IM therapy | 400 mg/day | 22 (88.0%) |
600 mg/day | 3 (12.0%) | |
Duration of preoperative therapy, months [range] |  | 8.96 ± 4.81[3–26] |
Preoperative maximal dimension, cm [range] |  | 11.48 ± 4.46 [4.5–24.4] |
Gene mutation, wild type vs. mutation | KIT in exon 9 | 22 vs. 3 |
KIT in exon 11 | 6 vs. 19 | |
KIT in exon 13 | 24 vs. 1 | |
KIT in exon 17 | 24 vs. 1 | |
PDGFRA in exon 12 | 25 vs. 0 | |
PDGFRA in exon 18(D842V) | 25 vs. 0 | |
Numbers of lesions | Single | 19 (76.0%) |
Multiple | 6 (24.0%) | |
Response to IM therapy (according to Choi criteria) | PR | 24 (96.0%) |
SD | 1 (4.0%) | |
PD | 0 (0.0%) | |
Margin status | R0 | 24 (96.0%) |
R1 | 0 (0.0%) | |
R2 | 1 (4.0%) | |
ECOG performance status | 0 | 18 (72.0%) |
1 | 7 (28.0%) |